Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001081010 | Cervix | CC | regulation of cell-substrate adhesion | 69/2311 | 221/18723 | 8.57e-14 | 5.69e-11 | 69 |
GO:00315898 | Cervix | CC | cell-substrate adhesion | 96/2311 | 363/18723 | 1.48e-13 | 8.85e-11 | 96 |
GO:01501159 | Cervix | CC | cell-substrate junction organization | 37/2311 | 101/18723 | 3.20e-10 | 4.46e-08 | 37 |
GO:00070448 | Cervix | CC | cell-substrate junction assembly | 34/2311 | 95/18723 | 3.35e-09 | 3.45e-07 | 34 |
GO:00019528 | Cervix | CC | regulation of cell-matrix adhesion | 40/2311 | 128/18723 | 1.32e-08 | 1.04e-06 | 40 |
GO:00071608 | Cervix | CC | cell-matrix adhesion | 60/2311 | 233/18723 | 1.58e-08 | 1.23e-06 | 60 |
GO:00343298 | Cervix | CC | cell junction assembly | 88/2311 | 420/18723 | 3.42e-07 | 1.38e-05 | 88 |
GO:01501169 | Cervix | CC | regulation of cell-substrate junction organization | 25/2311 | 71/18723 | 5.58e-07 | 2.06e-05 | 25 |
GO:00480417 | Cervix | CC | focal adhesion assembly | 28/2311 | 87/18723 | 9.86e-07 | 3.45e-05 | 28 |
GO:00518938 | Cervix | CC | regulation of focal adhesion assembly | 22/2311 | 66/18723 | 7.37e-06 | 1.73e-04 | 22 |
GO:00901098 | Cervix | CC | regulation of cell-substrate junction assembly | 22/2311 | 66/18723 | 7.37e-06 | 1.73e-04 | 22 |
GO:19018886 | Cervix | CC | regulation of cell junction assembly | 42/2311 | 204/18723 | 5.50e-04 | 5.29e-03 | 42 |
GO:00311224 | Cervix | CC | cytoplasmic microtubule organization | 14/2311 | 56/18723 | 6.93e-03 | 3.74e-02 | 14 |
GO:003158914 | Cervix | HSIL_HPV | cell-substrate adhesion | 30/737 | 363/18723 | 1.12e-04 | 2.34e-03 | 30 |
GO:001081014 | Cervix | HSIL_HPV | regulation of cell-substrate adhesion | 19/737 | 221/18723 | 1.22e-03 | 1.44e-02 | 19 |
GO:003432913 | Cervix | HSIL_HPV | cell junction assembly | 28/737 | 420/18723 | 4.82e-03 | 3.98e-02 | 28 |
GO:0034329 | Colorectum | AD | cell junction assembly | 136/3918 | 420/18723 | 2.02e-08 | 1.15e-06 | 136 |
GO:0010810 | Colorectum | AD | regulation of cell-substrate adhesion | 81/3918 | 221/18723 | 4.80e-08 | 2.55e-06 | 81 |
GO:0150115 | Colorectum | AD | cell-substrate junction organization | 44/3918 | 101/18723 | 2.38e-07 | 9.81e-06 | 44 |
GO:0031589 | Colorectum | AD | cell-substrate adhesion | 116/3918 | 363/18723 | 4.68e-07 | 1.76e-05 | 116 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLK | SNV | Missense_Mutation | rs771440768 | c.1735N>A | p.Glu579Lys | p.E579K | Q9H2G2 | protein_coding | tolerated(0.74) | benign(0.001) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLK | SNV | Missense_Mutation | novel | c.3034N>A | p.Glu1012Lys | p.E1012K | Q9H2G2 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AO-A0JC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
SLK | SNV | Missense_Mutation | | c.1360N>T | p.Asn454Tyr | p.N454Y | Q9H2G2 | protein_coding | deleterious(0.01) | benign(0.115) | TCGA-BH-A0DK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
SLK | SNV | Missense_Mutation | | c.688N>A | p.Glu230Lys | p.E230K | Q9H2G2 | protein_coding | deleterious(0) | benign(0.175) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLK | SNV | Missense_Mutation | novel | c.179N>A | p.Ala60Asp | p.A60D | Q9H2G2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
SLK | SNV | Missense_Mutation | novel | c.2483G>A | p.Arg828His | p.R828H | Q9H2G2 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SLK | SNV | Missense_Mutation | | c.1618N>T | p.Asp540Tyr | p.D540Y | Q9H2G2 | protein_coding | deleterious(0.01) | benign(0) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SLK | SNV | Missense_Mutation | rs554070501 | c.2774N>A | p.Arg925Gln | p.R925Q | Q9H2G2 | protein_coding | tolerated(0.06) | possibly_damaging(0.453) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SLK | SNV | Missense_Mutation | | c.64N>A | p.Glu22Lys | p.E22K | Q9H2G2 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
SLK | insertion | Nonsense_Mutation | novel | c.2732_2733insTAACTAGTATTTAAATTT | p.Gln911delinsHisAsnTerTyrLeuAsnLeu | p.Q911delinsHN*YLNL | Q9H2G2 | protein_coding | | | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9748 | SLK | DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE, KINASE | | ALISERTIB | ALISERTIB | |
9748 | SLK | DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE, KINASE | | CYC-116 | CYC-116 | |
9748 | SLK | DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE, KINASE | inhibitor | 249565620 | DANUSERTIB | |
9748 | SLK | DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE, KINASE | | SNS-314 | SNS-314 | |
9748 | SLK | DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE, KINASE | | OSI-632 | OSI-632 | |
9748 | SLK | DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE, KINASE | | ENTRECTINIB | ENTRECTINIB | |
9748 | SLK | DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE, KINASE | | BAY-613606 | CHEMBL541400 | |
9748 | SLK | DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE, KINASE | | RG-1530 | RG-1530 | |
9748 | SLK | DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE, KINASE | | GEFITINIB | GEFITINIB | |
9748 | SLK | DRUGGABLE GENOME, ENZYME, SERINE THREONINE KINASE, KINASE | | GW441756X | GW441756X | |